Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

The threshold effect analysis of the BRI on HGS. حسب Zhihao Wei (10909679)

"…</p><p>Methods</p><p>This study used cross-sectional data from the 2011–2014 National Health and Nutrition Examination Survey (NHANES) with complete data on BRI, HGS, and MQI. We used multivariate linear regression models and smooth curve fitting methods to explore the relationship between BRI and HGS and MQI. …"

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 1_Building radiomics models based on ACR TI-RADS combining clinical features for discriminating benign and malignant thyroid nodules.docx حسب Xingxing Chen (1569277)

"…To evaluate the clinical utility of the nomogram in reducing unnecessary biopsies, we further analyzed the performance of our integrated model (Clin+ACR+Rad) compared to the traditional ACR TI-RADS system at different probability thresholds. …"

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …"

Data Sheet 1_The Syringe Pump Gas Distribution (SPGD) system: a simple and low-cost method for simulating NH3/15NH3 deposition.docx حسب Chunze Wu (14348715)

"…The cost, complexity, and risk associated with simulating NH₃ deposition can be significantly decreased by utilizing the SPGD system. …"

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …"